s u m m a r y Apolipoprotein E (APOE) 34 genotype is associated with increased risk of Alzheimer's disease and other types of dementia. The level of cognitive dysfunction and its progression are also different in accordance with different APOE genotypes among Alzheimer's disease patients. Recently, essential tremor (ET) has become regarded as a multisystem disorder and many studies have shown that ET patients have cognitive deficits and an increased risk of dementia. The role of APOE 34 in ET patients, however, remains unidentified. In this study, we investigated the impact of APOE genotype on cognitive change in ET. Among the 69 patients enrolled, 10 patients had more than one APOE 34 allele. The neuropsychological data of the groups having APOE 34 and non-34 were similar: the proportion of cognitive impairment was not different between the 34 and non-34 groups. The results of our study suggest that the possibility of cognitive declines in ET is not influenced by the APOE 34 gene burden.
Introduction
Essential tremor (ET) is one of the most prevalent movement disorders. Its major symptoms are postural and kinetic tremors of the distal part of the body. Recent surveys have reported that ET is not a "pure" movement disorder, and has many aspects of nonmotor symptoms, such as cognitive dysfunctions, psycho-affective symptoms and cerebellar dysfunctions 1, 2 . A recent populationbased study in central Spain has shown that ET patients with tremor onset after 65 years of age were more likely to have dementia than the healthy control group 3 . Another prospective population-based study in New York found that ET was associated with both prevalence and risk of dementia 4 .
The apolipoprotein E (APOE) gene is the most prevalent gene for Alzheimer's disease (AD) and is likely to be involved in the pathogenesis of dementia 5, 6 . APOE 34 also has a key role in disease progression; carriers can experience faster and more severe cognitive decline as well as having more severe Ab deposition, gray matter atrophies, and cerebral blood flow derangement in structural and functional neuroimaging 7e9 .
The effects of this gene on other types of dementia or neurodegenerative disease have been widely studied 10 . A recent population-based, prospective study has found that APOE 34 is associated with an increased risk for vascular dementia in an allele dose-dependent fashion 11 . In addition, a high prevalence of APOE 34 was found in diffuse Lewy body disease 10 . However, no studies have been conducted regarding the impact of APOE 34 on cognitive change in patients with ET. Herein, we aimed to evaluate the impact of APOE 34 haplotype on the severity of cognitive dysfunctions in elderly patients with ET.
Methods

Participants
Sixty-nine consecutive newly-diagnosed ET patients were enrolled in this study. The evaluation procedure involved a detailed medical history, a physical and neurological examination, and a neuropsychological assessment. The patients' history of medical and neurological problems was obtained with consent from the patients and family members, or from other caregivers. All patients were diagnosed with having core criteria for the diagnosis of ET 12 .
These criteria include the presence of bilateral action (postural or kinetic) tremor of the hands and forearms in the absence of other neurological signs (with the exception of the cogwheel phenomena), or the presence of isolated head tremor with no signs of dystonia. The secondary criteria (duration >3 years, positive q All contributing authors declare no conflicts of interest.
family history, and beneficial response to alcohol) were also applied 12 . Young-onset patients ( 50 years) were excluded from this study because they were the least affected by cognitive change. Patients were also excluded from the study if: (1) they had neurological abnormalities related to systemic or other neurological diseases, (2) they were taking medications reported to influence cognition, such as anticholinergics or beta-blocking agents, or (3) they were found to have an FMR gene mutation of fragile X tremor and ataxia syndrome. Tremor severity was determined by the global tremor score 13 .
This was obtained by summing the following nine items: right and left arm tremor, as determined by history (two items); tremor at rest of either the face, lips or chin (one item); tremor at rest of all four limbs (four items); and action or postural tremor of both arms (two items), as determined by examination. This study was approved by the local ethics committee, and each patient provided written informed consent to participate.
Neuropsychological assessment
The patients' general cognitive status and severity of dementia were evaluated by the Korean version of the Mini-Mental State Examination, Clinical Dementia Rating (CDR), and the sum of box of CDR. Several cognitive domains were assessed by conducting a detailed battery of neuropsychological tests 14, 15 . Frontal motor functions were assessed by motor impersistence, contrasting program, goeno go test, fisteedgeepalm, alternating hand movement, alternating square and triangle, and Luria loop tests. The resulting scores of these tests were classified as abnormal if they were below the 16 th percentile of age-, sex-, and education-matched normal subjects 14 .
Dementia was diagnosed according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 21 . In line with the concept of mild cognitive impairment suggested by Petersen and colleagues 22 , the diagnosis of mild cognitive impairment (MCI) in patients with ET was made if at least one out of five cognitive domains were found to be abnormal.
Determination of APOE genotype
The detailed method used for APOE genotyping is described elsewhere. In brief, genomic DNA was extracted from whole-blood samples and amplified with polymerase chain reaction, as described by Wenham et al 23 .
Data analysis
The statistical analyses were performed using SPSS software version 15.0 (SPSS, Chicago, IL, USA). Comparisons of the demographics were done using the independent-sample t test for the continuous variables, and Pearson chi-squared test for the nominal variables. The general and specific neurocognitive functions were compared between APOE 34 and non-34 groups using the analysis of covariance, including age and education status as confounding covariates. Comparisons of APOE 34 allelic prevalence among normal cognition, MCI and dementia were performed using chisquared analysis. The level of statistical significance was set at p < 0.05.
Results
Among the 69 patients (including seven males and 62 females; mean age AE standard deviation: 66.5 AE 8.9 years), 31, 32 and six patients were assigned to the normal cognition, MCI, and dementia groups, respectively. The participants' mean disease duration was 7.0 AE 9.0 years and the mean duration of education was 8.1 AE 5.4 years. Ten patients had more than one APOE 34 genotype (APOE 32/ 34: 3, 33/ 34: 6 and 34/ 34: 1, respectively).
The data from the groups having APOE 34 and non-34 were similar for the age at examination and the age at onset, gender distribution, length of education, and presence of cardiovascular risk factors. The tremor severity, as measured by the global tremor score, was not statistically different between the two groups ( Table 1) .
There were no differences in general cognitive functions between APOE 34 and non-34 groups. The data also demonstrated that there were no significant differences in all cognitive domains. In addition, the proportion of cognitive impairment was not statistically different between the 34 and non-34 groups ( Table 2 ).
Discussion
The APOE gene is recognized as the most important and powerful genetic risk factor for AD. The APOE 34 genotype is likely to increase the risk of developing AD and lead to malignant clinical courses for both AD and MCI. APOE 34 influences AD pathology, interacting with the metabolism of amyloid precursor protein and with the accumulation of beta amyloid peptide, thus enhancing the hyperphosphorylation of tau protein and the formation of neurofibrillary tangles 5, 6 .
There were no data, however, about the influence of the APOE 34 gene burden on cognitive decline in patients with ET. In this study, we investigated the effect of the APOE genotype on the cognitive functions of ET, and found no significant difference in the distribution of cognitive diagnosis between APOE 34 and non-34 groups. In addition, the 34 allele did not influence any of the cognitive subdomains. This result suggests that cognitive declines in ET are not influenced by APOE 34 allele burden, and thus APOE 34 is probably not associated with poor cognitive outcome in ET.
Although many studies have shown that ET patients have cognitive deficits and an increased risk of dementia 2e4 , the 24 . In addition, multiple lines of evidence suggest that the circuitry involved includes the frontalesubcorticalecerebellar pathways, which play a role in both cognitive and affective processes in patients with ET 25e27 . There is, however, a lack of evidence for the substrates causing clinical and pathological changes because the Lewy bodies are confined within the locus ceruleus, and the influence of cerebellar degeneration on cognition is also unclear 24 . Moreover, these incidental neuropathological findings have been found in more than 10% of asymptomatic, elderly people 28 . Recent investigation on the microtubule-associated protein tau (MAPT) gene in ET patients showed the increasing frequency of MAPT H 1 haplotype was associated with an increasing risk of ET 29 . We can therefore speculate that the role of APOE in ET may be mechanistically distinct from that in other neurological disorders associated with APOE 34. The limitations of the present study include the fact that the number of patients enrolled was small and their diagnosis had not been pathologically or radiologically confirmed. To identify the precise role of the APOE gene, immunohistochemical staining or amyloid scan is more helpful. Another major weakness of this study is the absence of imaging characteristics that might identify patients with possible vascular or mixed dementia. Finally, the cognitive deficits in patients with ET may be the result of the misclassification of some patients with Parkinson's disease as having ET. In our cases, the duration of disease averaged 7.0 years; therefore, it is unlikely that any of these patients were in the early stages of Parkinson's disease.
In summary, this study suggests that APOE 34 allele burden does not influence the cognitive dysfunction of ET and the possibility of cognitive decline in ET is associated with other genetic/environmental factors. The case-control comparisons would be needed to identify the influencing of the APOE genotype in ET on the risk of cognitive dysfunction. 
